November 01, 2013
1 min read
Save

UT Southwestern names surgery chair

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Michael A. Choti, MD, has been named chair of UT Southwestern Medical Center’s department of surgery and surgeon-in-chief of William P. Clements Jr. University Hospital, scheduled to open next year.

Choti’s specialties include liver, pancreatic and other gastrointestinal cancers.

“There is no greater privilege than to have the opportunity to lead the UT Southwestern department of surgery,” Choti said in a press release. “I am particularly honored to assume such a position where there is both such a legacy of academic medicine and potential for the future. My goal is to lead the department into the challenging future of academic health care — building a premier department that leads in the excellence of person- and family-centered care, scientific discovery and surgical training. In addition, we want to serve our community in North Texas to the best of our ability.”

Choti spent 21 years at Johns Hopkins University School of Medicine. He most recently served as vice chair of the department of surgery and professor of surgery, oncology and radiology.

His research interests include experimental therapeutics, investigative therapy in gastrointestinal malignancies, molecular genetics related to cancer and cancer biology, clinical research in outcomes, and an interest in surgical innovation, computer-assisted surgery and robotics in cancer therapy.

His clinical interests focus on malignancies of the pancreas and liver.

He has served as Chair of NCI’s Cancer Therapy Evaluation Program Hepatobiliary Task Force, the American College of Surgeons’ Commission on Cancer, the GI committees of the National Surgical Adjuvant Breast and Bowel Project and American College of Surgeons’ Oncology Group, and the Colorectal Cancer and Neuroendocrine Tumors Guidelines Panels of the National Comprehensive Cancer Network.